Our people

LifeArc’s CEO Dr Melanie Lee, PhD, CBE. Prior to joining LifeArc Melanie pursued a 30 year career in healthcare R&D and gained leadership experience both from the biopharmaceutical industry and from the medical research charity sector.  Melanie’s previous roles have included Chief Scientific Officer at BTG (most recently) as well as senior positions at GSK, Celltech and UCB.  She has previously held Trustee appointments at Cancer Research Technology and Cancer Research UK and currently serves on the Board of Directors of Sanofi.

Message Melanie

General Counsel and Company Secretary. Edward also manages our Licensing team.

Message Edward

Justin runs our drug discovery and antibody engineering groups at the Centre for Therapeutics Discovery who work on small molecule and antibody projects.

Message Justin

As the Head of HR,  Amanda  is responsible for leading the people agenda within Life Arc.

Message Amanda

Mike heads up the Centre for Diagnostics Development (CDD), LifeArc’s translational activity seeking to develop novel diagnostic tests from cutting edge basic research. In addition, Mike is leading the creation of a scientific foresighting function at LifeArc to identify future charitable investment areas in translation and runs a small scientific due diligence team that assists the company in new project assessment and acquisition.

Message Michael

Andrew leads the team responsible for identifying, protecting and progressing promising life science research to improve human health.

Message Andrew

Andrew manages our Finance department, and also oversees our IT service.

Message Andrew

David Holbrook is Head of Seed Funds at Lifearc. 

Message David

Pauline is Investment Principal, LifeArc Seed Fund at LifeArc

Message Pauline

Andrew leads the team responsible for identifying, protecting and progressing promising life science research to improve human health.

Message Andrew

John heads a team responsible for identifying early stage targets, small molecules and monoclonal antibodies for our drug discovery group and the licensing of mature programmes to industry.

Message John

Roberto is responsible for identifying early stage targets, small molecules and monoclonal antibodies for our drug discovery group and the licensing of mature programmes to industry.

Message Roberto

Kevin is responsible for identifying early stage targets, small molecules and monoclonal antibodies for our drug discovery group and the licensing of mature programmes to industry.

Message Kevin

Derek is responsible for identifying early stage targets, small molecules and monoclonal antibodies for our drug discovery group and the licensing of mature programmes to industry.

Message Derek

Zhang is responsible for identifying early stage targets, small molecules and monoclonal antibodies for our drug discovery group and the licensing of mature programmes to industry, particularly in China.

Message Zhi

Nicole co-manages the Opportunity Assessment Group which has responsibility for reviewing and assessing new and existing opportunities for LifeArc. The team assesses scientific/technical potential as well as undertaking competitive and market analysis.

Message Nicole

Mike heads up the Centre for Diagnostics Development (CDD), LifeArc’s translational activity seeking to develop novel diagnostic tests from cutting edge basic research. In addition, Mike is leading the creation of a scientific foresighting function at LifeArc to identify future charitable investment areas in translation and runs a small scientific due diligence team that assists the company in new project assessment and acquisition.

Message Michael

Lorraine heads a team the Centre for Diagnostics Development (CDD), LifeArc’s translational activity seeking to develop novel diagnostic tests from cutting edge basic research.

Message Lorraine

Justin runs our drug discovery and antibody engineering groups at the Centre for Therapeutics Discovery who work on small molecule and antibody projects.

Message Justin

Katy is an Associate Director in LifeArc’s Centre for Therapeutics Discovery. She manages a team of biologists carrying out assay development and screening.

Message Katy

David heads up the BioTherapeutics team. The group develops therapeutic antibodies, this includes antibody generation, humanisation, affinity maturation and biophysical characterisation of candidates.

Message David

Message David

Andy manages a team of medicinal, analytical and computational chemists who carry out early stage drug discovery, including hit-to-lead development at our Centre for Therapeutics Discovery.

Message Andy

Andrew leads the team responsible for identifying, protecting and progressing promising life science research to improve human health.

Message Andrew

Mike covers the MRC LMB (PNAC and Neurobiology – shared), MRC The Gambia, MRC Uganda and the London School of Hygiene and Tropical Medicine (shared).

Message Mike

Rachael covers LMB PNAC (shared) and IGMM – ECRC.

Message Rachael

Georgia covers LMB Cell Biology, LMB PNAC (shared), LMB Neurobiology (shared) and MRC Mitchondrial Biology Unit (shared).

Message Georgia

Sam covers LMB Neurobiology Division, Mammalian Genetics Unit,  Mary Lyons Centre (MRC Harwell).

Message Sam

Karen covers LMB Structural Studies, Human Nutrition Research unit (shared), LMB NMR Facility and MRC Mitochondrial Biology Unit (shared).

Message Karen

Madhu looks after IP issues for our charity partners.

Message Madhu

Anji manages all IP, contractual and technology transfer matters arising from the MRC Prion Unit.

Message Anji

Message Francois-Xavier

Steven covers Institute of Genetics and Molecular Medicine (MMC & HGU) and MRC Clincal Sciences Centre (shared).

Message Steven

General Counsel and Company Secretary. Edward also manages our Licensing team.

Message Edward

Andrew manages our Finance department, and also oversees our IT service.

Message Andrew

For any finance enquiries please contact Mimi Ray at accountsenquiries@lifearc.org

Message Mimi

Paul heads IT team.

Message Paul